Haseeb Ahmad – Country President, Novartis UK
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Address: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Camberley, Surrey, GU16 7SR, United Kingdom
Tel: +44 (0)1276 692255
Web: http://www.novartis.co.uk/index.shtml
Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world. This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies – particularly in oncology, transplantation and ophthalmology. The company is also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 145 development projects in various stages of clinical development, including potential new products and potential new indications or formulations for existing products.
x Cardiovascular and Metabolism
x Hypertension, Diabetes, Atherosclerosis
x Integrated Speciality Medicines
x Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergies
x Infectious diseases, Transplantation and Immunology
x Organ transplants
x Neuroscience
x Alzheimer’s, Parkinson’s, Epilepsy, Multiple sclerosis
x Ophthalmics
x Age-related macular degeneration, Dry eye Haematologic and solid tumour diseases
Novartis Oncology aims to improve and extend the lives of patients with cancer. It has a wide range of therapy areas, and a broad pipeline of new products and new indications.
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
